Clinical data of GDC treatment cases with thrombus forming at coil-parent artery interface
| Case no. | Age (yr) | Sex | Location | Aneurysm Diameter (mm) | Aneurysm Neck (mm) | Ruptured | Procedural Therapy | Follow-up Therapy* | Evidence of Stroke at Discharge |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 54 | F | Ophthalmic | 6 × 3 | 5 | No | Abciximab | Aspirin, Plavix | No |
| 2 | 67 | F | Basilar tip | 5 | 3.5 | No | Abciximab | Aspirin | No |
| 3 | 55 | F | Basilar tip | 8 | 3.5 | No | Abciximab | Aspirin, Plavix | No |
| 4 | 45 | M | Basilar tip | 6 × 8 | 5 | Yes | Heparin | Aspirin | No |
| 5 | 49 | M | Basilar tip | 6 | 5 | Yes | Heparin | Aspirin | No |
| 6 | 43 | M | Posterior communicating | 12 × 20 | 5 | Yes | Heparin | Aspirin | No |
| 7 | 39 | M | Posterior communicating | 6 × 8 | 5 | Yes | Heparin | Aspirin | No |
| 8 | 57 | F | Superior hypophyseal | 10 | 6 | No | Integrilin and heparin | Aspirin | No |
| 9 | 49 | F | Superior hypophyseal | 12 | 8 | No | Abciximab | Aspirin,Plavix | No |
Note.—F indicates female; M, male.
* Aspirin, 325 mg/day; Plavix, 75 mg/day with 300 mg loading dose on day 1.